HEMA
Beijing Hema Co., Ltd. is a Chinese in vitro diagnostics manufacturer developing fluorescent microsphere POCT and chemiluminescence immunoassay reagents and instruments, serving hospitals, examination centers, and third-party laboratories across China.
- Company typePrivate
- Founded2007
- HeadquartersWesterville, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What HEMA does
HEMA (Beijing Hema Co., Ltd., with operating subsidiary Tianjin Hema Biomedical Co., Ltd.) is a Chinese in-vitro diagnostics manufacturer founded in Beijing in 2007 that develops quantitative immunodiagnostic reagents and instruments. The company runs two parallel technology platforms: a fluorescent microsphere dry quantitative POCT system (commercialized as the Savant-60 handheld, Savant-200 smart, and Savant-300 high-throughput instruments), and a fully automated magnetic microparticle chemiluminescence immunoassay analyzer. Its product catalogue spans more than 100 reagent SKUs across tumor markers (CEA, AFP, HE4, CA125, CA19-9, CA15-3, CA72-4, CA242, CA50, SCC, NSE, CYFRA21-1, F-PSA, t-PSA), thyroid function (FT3, FT4, TSH, TT3, TT4, TG-Ab, TPO-Ab), reproductive hormones (E2, FSH, LH, PRL, P, T, β-HCG), inflammation/cardiac/renal panels (CRP, PCT, SAA, IL-6, cTnI, NT-proBNP, D-Dimer, MPO, H-FABP, NGAL, Cys-C, RBP, MAU), bone metabolism (25-OH-D, PTH, P1NP, β-CTx, N-MID Osteocalcin), gastric function (PG I, PG II, G-17), liver fibrosis (CHI3L1), anemia/vitamins (Fer, FA, VB12), hepatitis (HBsAg/HBsAb/HBeAg/HBeAb/HBcAb), and a SARS-CoV-2 antigen test kit launched in 2022.
The company makes money through reagent (consumable) and instrument (hardware) sales to hospital laboratories, medical examination centers, and third-party medical testing laboratories across China, distributed through a direct sales force with service points in fourteen cities covering all of mainland China. Manufacturing is anchored at the Tianjin Beichen Economic and Technological Development Zone facility, which includes a GMP-compliant workshop and dedicated R&D space, reflecting a vertically integrated reagent-plus-instrument model. Quality system is certified to ISO 13485, and the company holds High-Tech Enterprise and External Quality Assessment certifications.
The commercial model is anchored on installed-instrument reagent pull-through, supplemented by the developer tools (academic webinars with the Chinese Medical Association Laboratory Medicine Branch, CMEF exhibitions, satellite symposia with academic hospitals) used to drive adoption among laboratorians and clinicians. Geographic exposure is 100% Mainland China aside from a single Philippines FDA registration, and the company appears to be founder-owned and self-funded without disclosed external venture, private-equity, or public-market financing.
HEMA firmographics
Firmographics- Name
- HEMA
- Legal name
- Beijing Hema Co., Ltd. (北京开云在线登录app官网-开云(中国)有限公司)
- Website
- https://hemahelp.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Beijing Hema Co., Ltd. is a Chinese in vitro diagnostics manufacturer developing fluorescent microsphere POCT and chemiluminescence immunoassay reagents and instruments, serving hospitals, examination centers, and third-party laboratories across China.
- Ownership category
- akta.pro rank
HEMA industry classification
Industry- Product category
- In Vitro Diagnostics (IVD)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
Keywords
Where HEMA is headquartered
LocationHeadquarters
- HQ city
- Westerville
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
HEMA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- IVD Reagent Sales: Sale of in vitro diagnostic reagents for various test categories including tumor markers, thyroid function, bone metabolism, renal function, cardiac markers, inflammation markers, hepatitis, diabetes, and reproductive/sex hormone testing. Products available in both chemiluminescence and fluorescent immunochromatography formats.
- Diagnostic Instrument Sales: Sale and distribution of diagnostic instruments including POCT devices (Savant-60, Savant-200, Savant-300) and fully automated chemiluminescence analyzers.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
HEMA product offering
Product offeringCore offering
HEMA develops, manufactures, and sells in vitro diagnostic (IVD) products consisting of point-of-care testing (POCT) and chemiluminescence immunoassay reagent kits alongside proprietary diagnostic instruments (Savant-60, Savant-200, Savant-300 POCT devices and a Magnetic Microparticle Automated Chemiluminescence Analyzer). Its reagent portfolio spans tumor markers, thyroid function, bone metabolism, renal function, cardiac markers, inflammation, hepatitis, diabetes, anemia, reproductive hormones, gastric function, liver fibrosis, and COVID-19 antigen detection, sold to hospitals, medical examination centers, and third-party medical testing centers across China.
Product overview
HEMA (HEMA Biotechnology) is a high-tech enterprise specializing in in vitro diagnostics (IVD), focusing on quantitative immune detection products. The company offers two main technology platforms: POCT (Point-of-Care Testing) using fluorescence microball dry quantitative technology, and Chemiluminescence Immunoassay (CLI) using magnetic microparticle technology. The product portfolio includes: (1) Four instrument models: Savant-60 (handheld POCT), Savant-200 (intelligent POCT with LIS/HIS connectivity), Savant-300 (high-throughput POCT with 120 tests/hour), and Magnetic Microparticle Automated Chemiluminescence Analyzer; (2) Over 100 reagent kits across multiple test categories including tumor markers (CA242, CA72-4, NSE, SCC, HE4, AFP, CEA, CA19-9, CA50, CA15-3, CYFRA21-1, PSA variants, CA125), thyroid function (FT3, FT4, TSH, TT3, TT4, TG-Ab, TPO-Ab), reproductive hormones (E2, FSH, LH, PRL, P, T, β-HCG, AMH, INHB), inflammation markers (CRP, PCT, SAA, IL-6), cardiac markers (cTnI, CK-MB, MYO, NT-proBNP, D-Dimer, MPO, H-FABP), bone metabolism (25-OH-D, 25-OH-D3, N-MID Osteocalcin, PTH, P1NP, β-CTx), liver fibrosis (CHI3L1), kidney function (NGAL, RBP, Cys-C, MAU), gastric function (PG I, PG II, G-17), anemia markers (Fer, FA, VB12), hepatitis markers (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb), and COVID-19 antigen tests. Products are sold to hospitals, medical examination centers, and third-party medical laboratories across China.
Differentiator
Problem solved
Functional benefit
Brands
- Savant POCT Series: Fluorescent microsphere dry quantitative POCT detection system including Savant-60, Savant-200, Savant-300 models
- Magnetic Particle Fully Automatic Chemiluminescence Analyzer
Products and services
- Savant POCT Instrument Series (Savant-60, Savant-200, Savant-300) Point-of-care testing instrument series: Savant-60 is a handheld POCT device for bedside or remote rapid diagnostics; Savant-200 is a smart POCT device with Android OS, 8-second per-test throughput, multiple quality control systems, and LIS/HIS connectivity for hospital data integration; Savant-300 has 20 independent constant-temperature incubation channels and processes up to 120 tests per hour for higher-throughput near-patient testing. Designed for hospital departments, emergency rooms, examination centers, and clinical laboratories across China.
- Magnetic Microparticle Automated Chemiluminescence Analyzer Fully automated chemiluminescence immunoassay analyzer using magnetic microparticle technology to deliver high-sensitivity, high-specificity quantitative detection of biomarkers for high-throughput clinical diagnostics in hospital central laboratories and third-party medical testing centers.
- Fluorescent Microsphere POCT Reagent Kit Series Quantitative POCT reagent kits run on the Savant series for cardiac markers (cTnI, MYO, CK-MB, NT-proBNP, D-Dimer, MPO, H-FABP), inflammation (CRP, PCT, SAA, IL-6), renal function (NGAL, Cys-C, RBP, MAU), bone metabolism (25-OH-D, 25-OH-D3, N-MID Osteocalcin, PTH, P1NP, β-CTx), gastric function (PG I, PG II, G-17), anemia (Ferritin, FA, VB12), vitamin D status, liver fibrosis (CHI3L1), reproductive hormones (AMH, INHB), and the 2022-launched COVID-19 antigen test. Sold to hospitals, examination centers, and third-party laboratories in China.
- Chemiluminescence Immunoassay Reagent Kit Series Quantitative chemiluminescence reagent kits run on the Magnetic Microparticle Automated Chemiluminescence Analyzer for thyroid function (FT3, FT4, TSH, TT3, TT4, TG-Ab, TPO-Ab), tumor markers (CEA, AFP, HE4, SCC, NSE, CA72-4, CA242, CYFRA21-1, CA15-3, CA125, CA19-9, CA50, F-PSA, t-PSA), reproductive hormones (E2, FSH, LH, PRL, Progesterone, Testosterone, β-HCG), hepatitis markers (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb), and diabetes indicators (C-Peptide, Insulin, Ferritin). Sold to hospital central laboratories and third-party medical laboratories in China.
- SARS-CoV-2 Antigen Test Kit (Fluorescence Immunochromatography) Rapid antigen detection kit for SARS-CoV-2 using dry fluorescent microsphere labeling and proprietary signal acquisition technology, intended for symptomatic individuals within 5 days of symptom onset, quarantine observation subjects, and self-testing use, with clinical trial compliance of 89.80% versus nucleic acid testing.
Quantifiable outcome
- COVID-19 antigen test achieved 89.80% compliance rate with nucleic acid testing results in clinical trials with 510 cases
- +1 more outcomes
Companies that use HEMA
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
HEMA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature3 records
HEMA partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- 中国医师协会 (Chinese Medical Doctor Association)minorCo-organization of National Children's Height Management and Bone Age Evaluation Advanced Training Workshop.
- 首都医科大学附属北京妇产医院 (Beijing Obstetrics and Gynecology Hospital, Capital Medical University)minorCo-organization of the Fourth Beijing Women's and Children's Health Laboratory Medicine Forum with satellite meeting and product exhibition support.
- 中华医学会检验医学分会 (Chinese Medical Association - Laboratory Medicine Branch)coreStrategic collaboration for medical education webinars. The partnership organizes the 'Medical Laboratory Testing Q&A' online classroom series covering various diagnostic topics including tumor markers, cardiac markers, renal markers, inflammation detection, and more. Expert lecturers from major hospitals participate.
- 四大医学检验中心 (Four Major Medical Testing Centers)corePartnership with four major independent medical testing laboratories for diagnostic product supply and service collaboration.
- 独立体检中心 (Independent Health Examination Centers)minorGroup collaboration agreements with independent health examination centers for diagnostic testing services.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
HEMA competitors and assessment
Company assessmentEmerging players
- Da An Gene (Daan Diagnostics / Kingmed Hybrid): Chinese diagnostics company historically strong in molecular diagnostics that has expanded into clinical immunoassay and chemiluminescence. Comparable to HEMA on being a China-based IVD reagent and instrument manufacturer targeting hospital and examination center customers, though with a different technology starting point.
Direct peers
- Autobio Diagnostics: Chinese IVD company specializing in chemiluminescence immunoassay analyzers and reagents (e.g., AutoLumo series) with a comparable menu of tumor markers, thyroid, reproductive, and infectious disease assays. Direct competitor to HEMA in mid- and large-tier Chinese hospitals and third-party medical laboratories.
- Snibe (Shenzhen New Industries Biomedical Engineering): China's leading domestic chemiluminescence immunoassay manufacturer with a broad tumor marker, thyroid, and infectious disease reagent menu. Directly comparable to HEMA on technology platform (fully automated chemiluminescence analyzers + reagent kits), customer base (Chinese hospitals and third-party labs), and business model (reagent-driven recurring revenue with installed-instrument pull-through), but at a much larger scale.
- Maccura Biotechnology: Sichuan-based Chinese IVD manufacturer with chemiluminescence, clinical chemistry, and POCT/molecular diagnostics lines. Closely comparable to HEMA on instrument-plus-reagent business model and Chinese hospital/clinical laboratory customer base, with overlapping menu categories in tumor, thyroid, and infectious disease.
Broad incumbents
- Mindray (Shenzhen Mindray Bio-Medical Electronics): Dominant Chinese IVD and medical device conglomerate whose chemiluminescence and CLIA reagent portfolio directly overlaps HEMA's menu. Mindray is a broader incumbent — patient monitoring, in-vitro diagnostics, and ultrasound — but its IVD division competes head-to-head with HEMA in Chinese hospital and examination center channels.
- Beckman Coulter Diagnostics: Multinational IVD incumbent whose DxI/Access chemiluminescence immunoassay systems overlap HEMA's menu in tumor, thyroid, reproductive, and cardiac markers. Sells into the same hospital and reference-lab channels in China through a broader clinical chemistry and immunoassay portfolio.
- Siemens Healthineers (Atellica / ADVIA Centaur): Global IVD player with the Atellica IM and ADVIA Centaur chemiluminescence platforms covering tumor markers, thyroid, reproductive, and infectious disease assays. Competes with HEMA in tertiary Chinese hospital labs and large commercial third-party laboratories.
- Abbott Diagnostics: Multinational IVD incumbent whose Architect/Alinity ci-series chemiluminescence analyzers and reagent menus (tumor, thyroid, cardiac, infectious disease) compete directly with HEMA in large Chinese hospitals. Operates as a broader incumbent across immunoassay, clinical chemistry, and point-of-care.
- Roche Diagnostics (China): Global IVD incumbent with the cobas/e601/e801 chemiluminescence platform and the broadest tumor marker, thyroid, cardiac, and infectious disease menus. Competes with HEMA in the same Chinese hospital laboratories, but at the high end of the market on installed base, automation, and assay breadth.
Regional players
- KingMed Diagnostics: China's largest independent third-party medical laboratory network. While primarily a clinical testing services provider rather than an IVD manufacturer, KingMed is one of HEMA's named strategic channel partners ('Four Major Medical Testing Centers') and a downstream customer, making it directly comparable on customer overlap and pull-through reagent demand.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
HEMA social profiles
Digital presenceHEMA compliance and trust
Trust signalCompliance6 records
HEMA financial estimates
Financial estimateRevenue estimate
Valuation estimate
HEMA leadership team
Management profileNumber of profiles
HEMA subsidiaries and ownership
Company hierarchySubsidiaries1 record
HEMA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HEMA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HEMA
What does HEMA do?
HEMA develops, manufactures, and sells in vitro diagnostic (IVD) products consisting of point-of-care testing (POCT) and chemiluminescence immunoassay reagent kits alongside proprietary diagnostic instruments (Savant-60, Savant-200, Savant-300 POCT devices and a Magnetic Microparticle Automated Chemiluminescence Analyzer). Its reagent portfolio spans tumor markers, thyroid function, bone metabolism, renal function, cardiac markers, inflammation, hepatitis, diabetes, anemia, reproductive hormones, gastric function, liver fibrosis, and COVID-19 antigen detection, sold to hospitals, medical examination centers, and third-party medical testing centers across China.
Is HEMA a public or private company?
HEMA is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was HEMA founded?
HEMA was founded in 2007. It employs 11 to 50 people.
Where is HEMA based?
HEMA is headquartered in Westerville, United States, in the North America region.
How does HEMA make money?
Two revenue lines are on record. IVD Reagent Sales are the primary driver. The others are diagnostic Instrument Sales.
Who are HEMA's main competitors?
Da An Gene (Daan Diagnostics / Kingmed Hybrid) is listed as an emerging player. Direct peers are Autobio Diagnostics, Snibe (Shenzhen New Industries Biomedical Engineering) and Maccura Biotechnology. Broad incumbents are Mindray (Shenzhen Mindray Bio-Medical Electronics), Beckman Coulter Diagnostics, Siemens Healthineers (Atellica / ADVIA Centaur), Abbott Diagnostics and Roche Diagnostics (China). KingMed Diagnostics is listed as a regional player.
Does HEMA have an API?
No public API is recorded for HEMA.
What industry is HEMA in?
HEMA's product category is In Vitro Diagnostics (IVD). Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument). Its NAICS code is 325413 and its SIC code is 2835.